TABLE 3.
pncA mutations reported in this studya
| Genotype | No. (%) of isolatesb | PZA susceptibility (database/literature)c | PZA susceptibility (CRT)d |
|---|---|---|---|
| D49N | 1 (0.55) | Resistant | Resistant |
| D8E | 2 (1.10) | Resistant | Resistant |
| F81S | 2 (1.10) | Susceptible | Susceptible |
| H51R | 9 (4.95) | Resistant | Resistant |
| H57L | 1 (0.55) | Resistant | Resistant |
| H71R | 2 (1.10) | Resistant | Resistant |
| I6S | 2 (1.10) | Resistant | Resistant |
| K48T | 8 (4.40) | Susceptible | Susceptible |
| P62S | 1 (0.55) | Susceptible | Susceptible |
| A-11G | 1 (0.55) | Resistant | Resistant |
| Q10P | 2 (1.10) | Resistant | Resistant |
| Q10R | 14 (7.69) | Resistant | Resistant |
| Δ375–389 | 1 (0.55) | Resistant | Resistant |
| Δ456–466 | 3 (1.65) | Resistant | Resistant |
| Wild type | 133 (73.08) | Susceptible | Susceptible |
a
Mutations observed among the putative promoter and pncA gene are shown, along with their corresponding PZA susceptibility phenotype, as defined by both the Tuberculosis Drug Resistance Mutation Database and our consensus reference test (CRT).
b
The percentage was calculated based on the total number of samples (n = 182).
c
According to the Tuberculosis Drug Resistance Mutation Database and the literature.
d
As determined by CRT (MGIT, Wayne assay, and pncA sequencing).